文献速递肝病消化道肿瘤与早癌

肝细胞癌监测的成本效益:获益与危害评估

Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

本研究构建马尔可夫模型,在100万模拟代偿期肝硬化患者中比较单纯超声、超声联合甲胎蛋白(AFP)与不监测三种策略,并纳入监测相关危害成本。结果显示超声联合AFP为优势策略,在支付意愿阈值每质量调整生命年10万美元下80.1%模拟中具成本效益。

要点

  • 在代偿期肝硬化患者中,超声联合AFP监测较单纯超声或不监测更具成本效益。
  • 超声联合AFP在80.1%的模拟中具成本效益(支付意愿阈值每质量调整生命年10万美元)。
  • HCC年发病率需>0.4%且半年一次监测依从性>19.5%,超声联合AFP才较不监测具成本效益。

核心结论

  • 在纳入监测相关获益与危害后,对代偿期肝硬化患者行超声联合AFP监测较单纯超声或不监测更具成本效益。

研究设计与样本

  • 构建马尔可夫模型,在100万模拟代偿期肝硬化患者中比较单纯超声、超声联合AFP与不监测三种策略。
  • 危害包括监测过程中因HCC行影像学检查和活检;模型输入基于文献综述,成本来自Medicare费用表并统一折算为2018年美元。
  • 主要结局为每增量质量调整生命年的增量成本效果比。

主要发现

  • 基础病例分析中,超声联合AFP为优于单纯超声和不监测的优势策略。
  • 概率敏感性分析中,在支付意愿阈值每质量调整生命年10万美元下,超声联合AFP在80.1%的模拟中为最具成本效益策略。
  • 阈值分析中,HCC年发病率>0.4%且半年一次监测依从性>19.5%是超声联合AFP较不监测具成本效益的必要条件。

关键数值与推荐

  • 超声联合AFP较不监测具成本效益所需条件:HCC年发病率>0.4%,半年一次监测依从性>19.5%。
  • 支付意愿阈值为每质量调整生命年10万美元时,超声联合AFP在80.1%的模拟中具成本效益。
  • 原文提及15%-20%的肝硬化患者在接受HCC监测时可观察到身体危害。

临床怎么用

  • 作者认为,在代偿期肝硬化患者中,超声联合AFP监测较单纯超声或不监测更具成本效益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The value of hepatocellular carcinoma (HCC) surveillance is defined by the balance of benefits, i.e., early tumor detection, and potential harms, related to false positive and indeterminate results. Although physical harms can be observed in 15%-20% of patients with cirrhosis undergoing HCC surveillance, previous cost-effectiveness analyses have not incorporated costs of harms. We aimed to evaluate the cost-effectiveness of HCC surveillance including both benefits and harms. DESIGN: We constructed a Markov model to compare surveillance strategies of ultrasound (US) alone, US and alpha fetoprotein (AFP), and no surveillance in 1 million simulated patients with compensated cirrhosis. Harms included imaging and biopsy in patients undergoing surveillance for HCC. Model inputs were based on literature review, and costs were derived from the Medicare fee schedule, with all costs inflated to 2018 dollars. The primary outcome was the incremental cost-effectiveness ratio per incremental quality-adjusted life-year. RESULTS: In the base case analysis, US with AFP was the dominant strategy over both US alone and no surveillance. In a probabilistic sensitivity analysis, US with AFP was the most cost-effective strategy in 80.1% of simulations at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year. In our threshold analyses, an HCC incidence >0.4% per year and surveillance adherence >19.5% biannually were necessary for US with AFP to be cost-effective compared with no surveillance. DISCUSSION: Accounting for both surveillance-related benefits and harms, US and AFP is more cost-effective for HCC surveillance than US alone or no surveillance in patients with compensated cirrhosis.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Parikh ND, Singal AG, Hutton DW, et al. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms. Am J Gastroenterol. 2020. PMID: 32530829. doi:10.14309/ajg.0000000000000715

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。